Lead Product(s) : Setmelanotide Acetate
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Rhythm Pharmaceuticals
Deal Size : $211.0 million
Deal Type : Acquisition
Details : Imcivree (setmelanotide) is a melanocortin 4 (MC4) receptor agonist indicated for chronic weight management in adult and pediatric patients 6 years of age and older with monogenic or syndromic obesity
Product Name : Imcivree
Product Type : Peptide
Upfront Cash : $5.0 million
February 27, 2023
Lead Product(s) : Setmelanotide Acetate
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Rhythm Pharmaceuticals
Deal Size : $211.0 million
Deal Type : Acquisition
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VecTabs, which are secreted- or intracellular-antibody fragments that are AAV-vectorized and delivered to neurons and/or astrocytes, have previously been shown to efficiently target such misfolded proteins (TDP-43) and toxic lipids (oxPL).
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
August 23, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VO659
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VICO’s lead antisense oligonucleotide product, VO659 is designed to suppress mutant proteins and slow or halt disease progression.
Product Name : VO659
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
July 29, 2021
Lead Product(s) : VO659
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Life Science Partners
Deal Size : $31.0 million
Deal Type : Series A Financing
Vico Therapeutics Raises $31 Million in Series A Financing Round
Details : Vico will use this funding to further advance its late preclinical stage Antisense OligoNucleotides lead platform for the development of therapies for different forms of Spinocerebellar Ataxia (SCA) and Huntington Disease (HD) into first-in-human clinica...
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
July 30, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Life Science Partners
Deal Size : $31.0 million
Deal Type : Series A Financing